-
Betibeglogene autotemcel, sold
under the
brand name
Zynteglo, is a gene
therapy for the
treatment for beta thal****emia. It was
developed by
Bluebird Bio...
- in the
European Union (EU) -
approved drug is
betibeglogene autotemcel (
Zynteglo),
which treats transfusion-dependent beta thal****emia (TDT), a rare genetic...
- very
young people.
Betibeglogene autotemcel, sold
under the
brand name
Zynteglo, is a gene
therapy for the
treatment for beta thal****emia. It was approved...
- bio
charges $2.8
million in the
United States for its one-time
treatment Zynteglo (betibeglogene autotemcel). Gene
editing therapies aimed at increasing...
-
expensive drug ever. In May, the EMA
approved betibeglogene autotemcel (
Zynteglo) for
treating beta thal****emia for
people twelve years of age and older...
- reimbur****t for
therapy cost. This
decision came
after the
withdrawal of
Zynteglo, a gene
therapy for
severe beta thal****emia, from
Germany in 2021 due to...
-
Beremagene geperpavec (Vyjuvek):
treatment of wounds.
Betibeglogene autotemcel (
Zynteglo):
treatment for beta thal****emia
Brexucabtagene autoleucel (Tecartus):...
- very
young people.
Betibeglogene autotemcel, sold
under the
brand name
Zynteglo, is a gene
therapy for the
treatment for beta thal****emia. It was approved...
- (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti); gene
therapies Zynteglo, Casgevy, Skysona, and Lyfgenia; and
various other cell
therapy products...
- (European
approval granted 2020).
Betibeglogene autotemcel (branded as
Zynteglo) for the
treatment of transfusion-dependent beta thal****emia (TDT), produced...
